1. Efficacy and Safety of Extracranial Vein Angioplasty in Multiple Sclerosis
- Author
-
Paolo, Zamboni, Luigi, Tesio, Stefania, Galimberti, Luca, Massacesi, Fabrizio, Salvi, Roberto, D’Alessandro, Patrizia, Cenni, Roberto, Galeotti, Donato, Papini, Roberto, D’Amico, Silvana, Simi, Maria Grazia Valsecchi, Graziella, Filippini, Group The Brave Dreams Research Group members: Stefano Ceruti, Paolo, Conforti, Anna Maria Malagoni, Erica, Menegatti, Mirko, Tessari, Francesca, Pancaldi, Maria Elena Vanini, Elena, Barbarossa, Ilaria, Bartolomei, Lisa, Pellegrino, Maria Grazia Piscaglia, Fabrizio, Rasi, Maria, Babini, Antonella, Drea, Eugenia, Guerrini, Enrico Maria Lotti, Agnese, Morelli, Milena, Peroni, Valentina, Zalambani, Sauro, Zecchini, Vittorio, Emanuele, Francesco, Patti, Clara, Chisari, Ignazio, Chiaramonte, Vincenzo, Cimino, Alessia, Giaquinta, Luigi Di Pino, Gianni, Failla, Pierfrancesco, Veroux, Roberto, Cantello, Maurizio, Leone, Lorenzo, Coppo, Giuseppe, Guizzardi, Olga, Raymkulova, Simona, Ruggerone, Alessandro, Stecco, Domizia, Vecchio, Paolo Agostino Confalonieri, Angela, Campanella, Valentina, Caldiera, Ciceri, E, Alessandra, Erbetta, Giuseppe, Faragò, Leila, Parma, Barbara, Reggiori, Valentina Torri Clerici, Maura, Danni, Salvatore, Arborino, Fabiana De Berardinis, Laura Di Biagio, Chiara, Orni, Rosita, Renzi, Pamela, Rosettani, Sara, Zagaglia, Giuseppe, Luccioni, Luigi, Oncini, Cristina, Quatrini, Zamboni, P, Tesio, L, Galimberti, S, Massacesi, L, Salvi, F, D'Alessandro, R, Cenni, P, Galeotti, R, Papini, D, D'Amico, R, Simi, S, Valsecchi, M, and Filippini, G
- Subjects
Male ,Time Factors ,CCSVI ,medicine.medical_treatment ,chronic cerebrospinal venous insufficiency ,Adolescent ,Adult ,Aged ,Angioplasty ,Double-Blind Method ,Female ,Follow-Up Studies ,Humans ,Image Processing, Computer-Assisted ,Italy ,Magnetic Resonance Imaging ,Middle Aged ,Multiple Sclerosis, Relapsing-Remitting ,Ultrasonography, Doppler, Color ,Young Adult ,Treatment Outcome ,030204 cardiovascular system & hematology ,law.invention ,Chronic cerebrospinal venous insufficiency (CCSVI) ,0302 clinical medicine ,Randomized controlled trial ,law ,Multiple Sclerosi ,Medicine ,multile sclerosis ,medicine.diagnostic_test ,chronic cerebrospinal venous insufficiency, multile sclerosis, venous percutaneous transluminal angioplasty, magnetic resonance imaging ,medicine.medical_specialty ,Chronic venous insufficiency ,Venography ,Socio-culturale ,venous percutaneous transluminal angioplasty ,03 medical and health sciences ,Intention-to-treat analysis ,business.industry ,Magnetic resonance imaging ,Odds ratio ,medicine.disease ,Surgery ,Chronic cerebrospinal venous insufficiency ,Neurology (clinical) ,multiple sclerosis, extracranial vein, angioplasty ,business ,030217 neurology & neurosurgery - Abstract
Importance Chronic cerebrospinal venous insufficiency (CCSVI) is characterized by restricted venous outflow from the brain and spinal cord. Whether this condition is associated with multiple sclerosis (MS) and whether venous percutaneous transluminal angioplasty (PTA) is beneficial in persons with MS and CCSVI is controversial. Objective To determine the efficacy and safety of venous PTA in patients with MS and CCSVI. Design, Setting, and Participants We analyzed 177 patients with relapsing-remitting MS; 62 were ineligible, including 47 (26.6%) who did not have CCSVI on color Doppler ultrasonography screening. A total of 115 patients were recruited in the study timeframe. All patients underwent a randomized, double-blind, sham-controlled, parallel-group trial in 6 MS centers in Italy. The trial began in August 2012 and concluded in March 2016; data were analyzed from April 2016 to September 2016. The analysis was intention to treat. Interventions Patients were randomly allocated (2:1) to either venous PTA or catheter venography without venous angioplasty (sham). Main Outcomes and Measures Two primary end points were assessed at 12 months: (1) a composite functional measure (ie, walking control, balance, manual dexterity, postvoid residual urine volume, and visual acuity) and (2) a measure of new combined brain lesions on magnetic resonance imaging, including the proportion of lesion-free patients. Combined lesions included T1 gadolinium-enhancing lesions plus new or enlarged T2 lesions. Results Of the included 115 patients with relapsing-remitting MS, 76 were allocated to the PTA group (45 female [59%]; mean [SD] age, 40.0 [10.3] years) and 39 to the sham group (29 female [74%]; mean [SD] age, 37.5 [10.6] years); 112 (97.4%) completed follow-up. No serious adverse events occurred. Flow restoration was achieved in 38 of 71 patients (54%) in the PTA group. The functional composite measure did not differ between the PTA and sham groups (41.7% vs 48.7%; odds ratio, 0.75; 95% CI, 0.34-1.68;P = .49). The mean (SD) number of combined lesions on magnetic resonance imaging at 6 to 12 months were 0.47 (1.19) in the PTA group vs 1.27 (2.65) in the sham group (mean ratio, 0.37; 95% CI, 0.15-0.91;P = .03: adjustedP = .09) and were 1.40 (4.21) in the PTA group vs 1.95 (3.73) in the sham group at 0 to 12 months (mean ratio, 0.72; 95% CI, 0.32-1.63;P = .45; adjustedP = .45). At follow-up after 6 to 12 months, 58 of 70 patients (83%) in the PTA group and 22 of 33 (67%) in the sham group were free of new lesions on magnetic resonance imaging (odds ratio, 2.64; 95% CI, 1.11-6.28;P = .03; adjustedP = .09). At 0 to 12 months, 46 of 73 patients (63.0%) in the PTA group and 18 of 37 (49%) in the sham group were free of new lesions on magnetic resonance imaging (odds ratio, 1.80; 95% CI, 0.81-4.01;P = .15; adjustedP = .30). Conclusion and Relevance Venous PTA has proven to be a safe but largely ineffective technique; the treatment cannot be recommended in patients with MS. Trial Registration clinicaltrials.gov Identifier:NCT01371760
- Published
- 2018
- Full Text
- View/download PDF